| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 30 | 2024 | 134 | 4.880 |
Why?
|
| Societies, Medical | 21 | 2025 | 794 | 4.130 |
Why?
|
| Spinal Neoplasms | 22 | 2018 | 74 | 3.500 |
Why?
|
| Chronic Pain | 8 | 2024 | 159 | 2.400 |
Why?
|
| Evidence-Based Medicine | 15 | 2025 | 644 | 2.350 |
Why?
|
| Shoulder Pain | 3 | 2025 | 21 | 2.170 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 17 | 2024 | 99 | 1.600 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2025 | 3911 | 1.500 |
Why?
|
| Diagnostic Imaging | 10 | 2025 | 300 | 1.490 |
Why?
|
| Brain Neoplasms | 16 | 2024 | 1297 | 1.430 |
Why?
|
| Arthralgia | 10 | 2024 | 77 | 1.360 |
Why?
|
| Acute Pain | 2 | 2025 | 18 | 1.120 |
Why?
|
| Fractures, Stress | 2 | 2024 | 15 | 1.000 |
Why?
|
| Meningeal Neoplasms | 7 | 2024 | 205 | 1.000 |
Why?
|
| Breast Neoplasms | 6 | 2022 | 2646 | 0.970 |
Why?
|
| Shoulder Injuries | 1 | 2025 | 11 | 0.910 |
Why?
|
| Arthrography | 1 | 2023 | 6 | 0.820 |
Why?
|
| Crystal Arthropathies | 1 | 2023 | 5 | 0.800 |
Why?
|
| Radiotherapy, Intensity-Modulated | 6 | 2014 | 100 | 0.770 |
Why?
|
| Spinal Cord Compression | 4 | 2018 | 31 | 0.740 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2022 | 87 | 0.730 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 69 | 0.730 |
Why?
|
| Osteoarthritis | 1 | 2023 | 104 | 0.700 |
Why?
|
| Humans | 109 | 2025 | 131504 | 0.700 |
Why?
|
| United States | 21 | 2025 | 11794 | 0.670 |
Why?
|
| Cranial Irradiation | 3 | 2021 | 73 | 0.670 |
Why?
|
| Bone and Bones | 4 | 2023 | 305 | 0.670 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2025 | 2116 | 0.630 |
Why?
|
| Neurofibromin 1 | 2 | 2020 | 49 | 0.630 |
Why?
|
| GTP Phosphohydrolases | 3 | 2022 | 159 | 0.620 |
Why?
|
| Schizosaccharomyces pombe Proteins | 5 | 2000 | 35 | 0.620 |
Why?
|
| Schizosaccharomyces | 5 | 2000 | 64 | 0.610 |
Why?
|
| Radiotherapy, Conformal | 5 | 2007 | 51 | 0.600 |
Why?
|
| ras Proteins | 6 | 2020 | 146 | 0.590 |
Why?
|
| Estrogen Receptor alpha | 2 | 2020 | 434 | 0.580 |
Why?
|
| Glioblastoma | 6 | 2014 | 346 | 0.570 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 217 | 0.570 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2016 | 245 | 0.540 |
Why?
|
| Skull Base Neoplasms | 4 | 2014 | 37 | 0.540 |
Why?
|
| Spinal Cord Neoplasms | 5 | 2014 | 68 | 0.520 |
Why?
|
| Proton Therapy | 5 | 2014 | 156 | 0.520 |
Why?
|
| Cartilage, Articular | 3 | 2022 | 63 | 0.510 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 239 | 0.510 |
Why?
|
| Radiotherapy Dosage | 15 | 2024 | 214 | 0.500 |
Why?
|
| Ankle Injuries | 1 | 2016 | 31 | 0.500 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 909 | 0.490 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2016 | 12 | 0.490 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1910 | 0.490 |
Why?
|
| Eukaryotic Initiation Factors | 3 | 2000 | 36 | 0.480 |
Why?
|
| Genes, ras | 2 | 2015 | 99 | 0.470 |
Why?
|
| Interleukin-8 | 2 | 2020 | 207 | 0.470 |
Why?
|
| Chordoma | 3 | 2014 | 18 | 0.470 |
Why?
|
| Hemangiopericytoma | 2 | 2013 | 9 | 0.470 |
Why?
|
| Fungal Proteins | 4 | 2000 | 132 | 0.430 |
Why?
|
| Meningioma | 3 | 2024 | 135 | 0.430 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 139 | 0.420 |
Why?
|
| Carrier Proteins | 4 | 2014 | 1024 | 0.410 |
Why?
|
| Kidney Neoplasms | 4 | 2016 | 454 | 0.400 |
Why?
|
| Middle Aged | 38 | 2020 | 28839 | 0.400 |
Why?
|
| Chondrosarcoma | 2 | 2014 | 13 | 0.390 |
Why?
|
| Aged, 80 and over | 18 | 2019 | 6916 | 0.390 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2015 | 152 | 0.380 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2023 | 397 | 0.380 |
Why?
|
| Eukaryotic Initiation Factor-3 | 2 | 2010 | 10 | 0.380 |
Why?
|
| Combined Modality Therapy | 12 | 2015 | 1258 | 0.360 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2012 | 28 | 0.360 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 711 | 0.360 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2012 | 24 | 0.360 |
Why?
|
| Aged | 30 | 2019 | 21238 | 0.360 |
Why?
|
| Adult | 36 | 2022 | 31666 | 0.350 |
Why?
|
| Cortical Bone | 2 | 2023 | 4 | 0.350 |
Why?
|
| Craniospinal Irradiation | 1 | 2012 | 60 | 0.350 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2014 | 293 | 0.350 |
Why?
|
| Models, Biological | 2 | 2015 | 1390 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2017 | 1276 | 0.330 |
Why?
|
| Stereotaxic Techniques | 3 | 2016 | 98 | 0.330 |
Why?
|
| Extremities | 2 | 2023 | 77 | 0.320 |
Why?
|
| Algorithms | 4 | 2016 | 1685 | 0.320 |
Why?
|
| Female | 41 | 2022 | 71087 | 0.320 |
Why?
|
| Mammary Glands, Human | 1 | 2010 | 81 | 0.310 |
Why?
|
| Spindle Apparatus | 2 | 2000 | 47 | 0.310 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 239 | 0.310 |
Why?
|
| Ankle | 2 | 2020 | 29 | 0.300 |
Why?
|
| Signal Transduction | 6 | 2020 | 4674 | 0.300 |
Why?
|
| Saccharomyces cerevisiae | 6 | 1995 | 403 | 0.290 |
Why?
|
| Radiation Injuries | 5 | 2016 | 145 | 0.290 |
Why?
|
| Stroke | 1 | 2016 | 1049 | 0.280 |
Why?
|
| Knee Joint | 4 | 2022 | 173 | 0.280 |
Why?
|
| Cell Cycle Proteins | 4 | 2010 | 703 | 0.270 |
Why?
|
| Mice, Nude | 3 | 2020 | 714 | 0.270 |
Why?
|
| Protein Biosynthesis | 1 | 2010 | 579 | 0.270 |
Why?
|
| Online Systems | 1 | 2007 | 17 | 0.260 |
Why?
|
| Male | 40 | 2025 | 65158 | 0.260 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 3672 | 0.250 |
Why?
|
| Ultrasonography | 4 | 2020 | 972 | 0.250 |
Why?
|
| Brain Edema | 1 | 2007 | 65 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 5 | 2024 | 1305 | 0.240 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 2985 | 0.240 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 1999 | 102 | 0.240 |
Why?
|
| Radiopharmaceuticals | 2 | 2024 | 165 | 0.240 |
Why?
|
| Bone Density | 2 | 2019 | 363 | 0.230 |
Why?
|
| Sciatic Nerve | 1 | 2025 | 59 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2000 | 600 | 0.230 |
Why?
|
| Porosity | 4 | 2023 | 43 | 0.230 |
Why?
|
| Palliative Care | 2 | 2015 | 444 | 0.230 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2025 | 37 | 0.230 |
Why?
|
| Superoxide Dismutase | 3 | 1991 | 179 | 0.230 |
Why?
|
| Spinal Injuries | 1 | 2025 | 33 | 0.220 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2024 | 16 | 0.220 |
Why?
|
| Nerve Regeneration | 1 | 2025 | 76 | 0.220 |
Why?
|
| Elbow Joint | 1 | 2024 | 13 | 0.220 |
Why?
|
| Forearm | 1 | 2024 | 38 | 0.220 |
Why?
|
| Ki-67 Antigen | 2 | 2022 | 104 | 0.220 |
Why?
|
| Sacrum | 3 | 2021 | 28 | 0.220 |
Why?
|
| Organometallic Compounds | 1 | 2024 | 112 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 79 | 0.210 |
Why?
|
| Nerve Degeneration | 1 | 2025 | 129 | 0.210 |
Why?
|
| Pain Measurement | 2 | 2016 | 354 | 0.210 |
Why?
|
| World Health Organization | 1 | 2024 | 115 | 0.210 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 72 | 0.210 |
Why?
|
| Consensus | 2 | 2016 | 565 | 0.210 |
Why?
|
| Treatment Failure | 6 | 2017 | 353 | 0.200 |
Why?
|
| Hand | 1 | 2024 | 98 | 0.200 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2023 | 4 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2018 | 1078 | 0.200 |
Why?
|
| Wrist | 1 | 2023 | 28 | 0.200 |
Why?
|
| Shoulder | 1 | 2023 | 32 | 0.200 |
Why?
|
| Radiography | 3 | 2023 | 760 | 0.200 |
Why?
|
| Supine Position | 1 | 2003 | 22 | 0.200 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2025 | 215 | 0.190 |
Why?
|
| Skull Neoplasms | 1 | 2003 | 15 | 0.190 |
Why?
|
| Disease Progression | 3 | 2022 | 2205 | 0.190 |
Why?
|
| Elbow | 1 | 2022 | 8 | 0.190 |
Why?
|
| Radiometry | 1 | 2003 | 47 | 0.190 |
Why?
|
| Osteonecrosis | 1 | 2022 | 17 | 0.190 |
Why?
|
| Tumor Burden | 5 | 2019 | 239 | 0.190 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 5277 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 2 | 2022 | 647 | 0.190 |
Why?
|
| Meningitis | 1 | 2003 | 98 | 0.190 |
Why?
|
| X-Ray Microtomography | 3 | 2023 | 101 | 0.190 |
Why?
|
| Knee | 2 | 2020 | 21 | 0.190 |
Why?
|
| Cadaver | 3 | 2021 | 120 | 0.180 |
Why?
|
| Prognosis | 8 | 2021 | 4951 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 755 | 0.180 |
Why?
|
| Brain | 5 | 2023 | 3237 | 0.180 |
Why?
|
| Cauda Equina | 1 | 2021 | 9 | 0.180 |
Why?
|
| Spine | 3 | 2016 | 148 | 0.180 |
Why?
|
| Glioma | 2 | 2024 | 498 | 0.180 |
Why?
|
| Ependymoma | 3 | 2014 | 153 | 0.170 |
Why?
|
| Organs at Risk | 4 | 2016 | 40 | 0.170 |
Why?
|
| Chromosomes, Fungal | 1 | 2000 | 49 | 0.170 |
Why?
|
| Cell Nucleus | 2 | 2020 | 567 | 0.170 |
Why?
|
| Chromosome Segregation | 1 | 2000 | 71 | 0.170 |
Why?
|
| Hemarthrosis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 20 | 0.160 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 301 | 0.160 |
Why?
|
| Foot Injuries | 1 | 2020 | 8 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2021 | 426 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 56 | 0.160 |
Why?
|
| Social Class | 1 | 2021 | 211 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 30 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2003 | 207 | 0.160 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 38 | 0.160 |
Why?
|
| Elastic Modulus | 2 | 2021 | 32 | 0.160 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 1404 | 0.160 |
Why?
|
| Young Adult | 9 | 2020 | 10092 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 1001 | 0.160 |
Why?
|
| Immune System | 1 | 2020 | 98 | 0.150 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 195 | 0.150 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 92 | 0.150 |
Why?
|
| Musculoskeletal Diseases | 1 | 2020 | 56 | 0.150 |
Why?
|
| Phantoms, Imaging | 3 | 2007 | 147 | 0.150 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 209 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 59 | 0.150 |
Why?
|
| Cartilage Diseases | 1 | 2019 | 17 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2000 | 251 | 0.150 |
Why?
|
| Bone Diseases | 1 | 2019 | 44 | 0.150 |
Why?
|
| Flunarizine | 1 | 2018 | 2 | 0.150 |
Why?
|
| Immobilization | 2 | 2017 | 23 | 0.150 |
Why?
|
| Mice, SCID | 1 | 2020 | 579 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 179 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2020 | 349 | 0.140 |
Why?
|
| Hip Fractures | 1 | 2019 | 68 | 0.140 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2567 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 739 | 0.140 |
Why?
|
| Survival Rate | 8 | 2016 | 2149 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2019 | 227 | 0.130 |
Why?
|
| Animals | 8 | 2025 | 34341 | 0.130 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 29 | 0.130 |
Why?
|
| Students, Medical | 1 | 2022 | 350 | 0.130 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 1405 | 0.130 |
Why?
|
| Treatment Outcome | 12 | 2016 | 12936 | 0.130 |
Why?
|
| Patient Positioning | 1 | 2017 | 53 | 0.130 |
Why?
|
| Dacarbazine | 2 | 2014 | 93 | 0.130 |
Why?
|
| Hip Joint | 1 | 2017 | 53 | 0.130 |
Why?
|
| Nervous System Diseases | 2 | 2016 | 403 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 109 | 0.130 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 199 | 0.130 |
Why?
|
| Ankle Joint | 1 | 2016 | 36 | 0.120 |
Why?
|
| Arthritis | 1 | 2017 | 85 | 0.120 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 84 | 0.120 |
Why?
|
| Meniscus | 1 | 2016 | 2 | 0.120 |
Why?
|
| Legg-Calve-Perthes Disease | 1 | 2016 | 3 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 704 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 514 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 221 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 765 | 0.120 |
Why?
|
| Adolescent | 17 | 2017 | 20917 | 0.120 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1995 | 264 | 0.120 |
Why?
|
| Muscle Spasticity | 1 | 2016 | 56 | 0.120 |
Why?
|
| Mutation | 5 | 2020 | 6177 | 0.120 |
Why?
|
| Osteoporosis | 1 | 2017 | 134 | 0.120 |
Why?
|
| Whole-Body Irradiation | 1 | 2015 | 61 | 0.120 |
Why?
|
| Back Pain | 1 | 2015 | 30 | 0.120 |
Why?
|
| Genes, Fungal | 2 | 1995 | 60 | 0.120 |
Why?
|
| Compressive Strength | 1 | 2015 | 11 | 0.120 |
Why?
|
| Microtubules | 3 | 2000 | 128 | 0.110 |
Why?
|
| Molecular Sequence Data | 8 | 2005 | 3614 | 0.110 |
Why?
|
| Tensile Strength | 1 | 2015 | 46 | 0.110 |
Why?
|
| Autophagy | 1 | 2018 | 424 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 76 | 0.110 |
Why?
|
| Cachexia | 1 | 2015 | 50 | 0.110 |
Why?
|
| Age Factors | 3 | 2015 | 2870 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1614 | 0.110 |
Why?
|
| Retrospective Studies | 16 | 2014 | 17648 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2143 | 0.110 |
Why?
|
| Sarcoma | 1 | 2017 | 210 | 0.110 |
Why?
|
| Isotretinoin | 1 | 2014 | 19 | 0.110 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 124 | 0.110 |
Why?
|
| Thalidomide | 1 | 2014 | 40 | 0.110 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 178 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 865 | 0.110 |
Why?
|
| Image Enhancement | 1 | 2015 | 172 | 0.100 |
Why?
|
| Mice | 4 | 2021 | 18473 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 98 | 0.100 |
Why?
|
| Syndrome | 1 | 2016 | 1166 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2016 | 155 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 275 | 0.100 |
Why?
|
| Protons | 3 | 2009 | 100 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 248 | 0.100 |
Why?
|
| Methionine | 2 | 1990 | 96 | 0.100 |
Why?
|
| Spinal Cord Injuries | 1 | 2016 | 278 | 0.100 |
Why?
|
| Survival Analysis | 5 | 2007 | 1522 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 323 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2016 | 272 | 0.090 |
Why?
|
| Radiation Dosage | 3 | 2015 | 135 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2012 | 296 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2014 | 296 | 0.090 |
Why?
|
| Karnofsky Performance Status | 3 | 2015 | 13 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2015 | 685 | 0.090 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2012 | 81 | 0.090 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2011 | 12 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 30 | 0.090 |
Why?
|
| Protein Binding | 2 | 2010 | 1710 | 0.090 |
Why?
|
| Efficiency | 1 | 2012 | 71 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2014 | 358 | 0.090 |
Why?
|
| Neoplasms | 3 | 2014 | 2969 | 0.090 |
Why?
|
| Brain Stem Neoplasms | 1 | 2011 | 41 | 0.090 |
Why?
|
| Radiology | 3 | 2017 | 126 | 0.090 |
Why?
|
| Macromolecular Substances | 2 | 2022 | 141 | 0.090 |
Why?
|
| Ubiquitination | 1 | 2012 | 173 | 0.090 |
Why?
|
| Mastoid | 1 | 2011 | 25 | 0.090 |
Why?
|
| Ear, Middle | 1 | 2011 | 24 | 0.080 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2010 | 20 | 0.080 |
Why?
|
| Polyribosomes | 1 | 2010 | 23 | 0.080 |
Why?
|
| Spinal Cord | 2 | 2016 | 266 | 0.080 |
Why?
|
| F-Box Proteins | 1 | 2010 | 32 | 0.080 |
Why?
|
| Base Sequence | 6 | 2000 | 2782 | 0.080 |
Why?
|
| Sulfates | 1 | 1990 | 34 | 0.080 |
Why?
|
| Linear Models | 2 | 2014 | 695 | 0.080 |
Why?
|
| Ribosomes | 1 | 2010 | 124 | 0.080 |
Why?
|
| Tibia | 2 | 2021 | 81 | 0.080 |
Why?
|
| Arsenicals | 1 | 1989 | 18 | 0.080 |
Why?
|
| Oxides | 1 | 1989 | 16 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 230 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1254 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2363 | 0.080 |
Why?
|
| Arsenites | 1 | 1989 | 19 | 0.080 |
Why?
|
| Tubulin | 2 | 2000 | 75 | 0.080 |
Why?
|
| Pain Management | 1 | 2012 | 199 | 0.080 |
Why?
|
| Acute Disease | 2 | 2025 | 1153 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2012 | 464 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 631 | 0.080 |
Why?
|
| Manganese | 1 | 1989 | 60 | 0.070 |
Why?
|
| Superoxides | 1 | 1989 | 129 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 1990 | 301 | 0.070 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2010 | 257 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 617 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 1989 | 178 | 0.070 |
Why?
|
| Photons | 1 | 2009 | 64 | 0.070 |
Why?
|
| Arsenic | 1 | 1989 | 48 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 1988 | 0.070 |
Why?
|
| Child | 11 | 2016 | 26239 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 363 | 0.070 |
Why?
|
| Epidural Space | 1 | 2007 | 13 | 0.070 |
Why?
|
| Biomechanical Phenomena | 2 | 2021 | 265 | 0.070 |
Why?
|
| Survival | 1 | 2007 | 15 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2024 | 6485 | 0.070 |
Why?
|
| Germinoma | 1 | 2006 | 31 | 0.060 |
Why?
|
| Medical Records | 1 | 2007 | 180 | 0.060 |
Why?
|
| Chest Pain | 1 | 2007 | 125 | 0.060 |
Why?
|
| Pain | 1 | 2009 | 439 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2011 | 828 | 0.060 |
Why?
|
| Oxygen | 1 | 1989 | 552 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 785 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 569 | 0.060 |
Why?
|
| Pelvic Bones | 1 | 2005 | 27 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2016 | 330 | 0.060 |
Why?
|
| Rats, Inbred Lew | 1 | 2025 | 67 | 0.060 |
Why?
|
| Thymosin | 1 | 2005 | 22 | 0.060 |
Why?
|
| Child, Preschool | 6 | 2013 | 15047 | 0.060 |
Why?
|
| Recurrence | 3 | 2017 | 1478 | 0.060 |
Why?
|
| Contrast Media | 2 | 2019 | 490 | 0.060 |
Why?
|
| Genetic Complementation Test | 3 | 1994 | 87 | 0.050 |
Why?
|
| Retinoblastoma | 1 | 2005 | 87 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2015 | 955 | 0.050 |
Why?
|
| Retinal Neoplasms | 1 | 2005 | 74 | 0.050 |
Why?
|
| GTP-Binding Proteins | 2 | 1995 | 161 | 0.050 |
Why?
|
| Infant | 5 | 2013 | 13300 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1160 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 340 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 792 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 344 | 0.050 |
Why?
|
| Decision Trees | 1 | 2003 | 57 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 119 | 0.050 |
Why?
|
| Calibration | 1 | 2003 | 95 | 0.050 |
Why?
|
| Eye Neoplasms | 1 | 2003 | 38 | 0.050 |
Why?
|
| Cranial Nerve Diseases | 1 | 2003 | 28 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2005 | 265 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 4037 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 1417 | 0.050 |
Why?
|
| Astrocytoma | 1 | 2003 | 102 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 432 | 0.050 |
Why?
|
| Texas | 1 | 2011 | 3614 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 2005 | 320 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2013 | 8589 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2013 | 226 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3834 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 364 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2005 | 384 | 0.040 |
Why?
|
| Spinal Nerve Roots | 1 | 2021 | 18 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4684 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2021 | 67 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 120 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 1356 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 102 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 1999 | 1745 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 444 | 0.040 |
Why?
|
| DNA, Fungal | 1 | 2000 | 76 | 0.040 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 17 | 0.040 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2020 | 21 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2005 | 2562 | 0.040 |
Why?
|
| Physical Therapists | 1 | 2020 | 7 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2003 | 365 | 0.040 |
Why?
|
| Perception | 1 | 2022 | 228 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 634 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2000 | 773 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 102 | 0.040 |
Why?
|
| Hemophilia A | 1 | 2020 | 31 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 159 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2019 | 117 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2000 | 334 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2021 | 156 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 39 | 0.040 |
Why?
|
| Nurses | 1 | 2020 | 79 | 0.040 |
Why?
|
| Rats | 1 | 2025 | 3454 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 313 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 319 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2018 | 28 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2022 | 494 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 111 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 1999 | 157 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1809 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 4517 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 832 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 350 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 1999 | 382 | 0.030 |
Why?
|
| Proteolysis | 1 | 2018 | 190 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 1999 | 312 | 0.030 |
Why?
|
| Kinetics | 2 | 1989 | 1101 | 0.030 |
Why?
|
| Technetium | 1 | 2017 | 16 | 0.030 |
Why?
|
| Cell Division | 1 | 1999 | 725 | 0.030 |
Why?
|
| Risk Factors | 3 | 2017 | 10952 | 0.030 |
Why?
|
| Melanoma | 1 | 2004 | 920 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1995 | 624 | 0.030 |
Why?
|
| Femur | 1 | 2017 | 74 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Radiation Oncologists | 1 | 2016 | 3 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 1617 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2017 | 46 | 0.030 |
Why?
|
| Neurosurgeons | 1 | 2016 | 16 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 66 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 85 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2020 | 900 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 91 | 0.030 |
Why?
|
| Sequence Deletion | 2 | 1995 | 515 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 1999 | 657 | 0.030 |
Why?
|
| Alleles | 2 | 1991 | 1709 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.030 |
Why?
|
| Terminally Ill | 1 | 2015 | 26 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 161 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 1347 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein, Saccharomyces cerevisiae | 1 | 1994 | 2 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 33 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2014 | 7 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 1993 | 174 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2015 | 282 | 0.030 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2014 | 6 | 0.030 |
Why?
|
| Celecoxib | 1 | 2014 | 34 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2017 | 207 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 113 | 0.030 |
Why?
|
| Parotid Neoplasms | 1 | 2014 | 19 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2692 | 0.030 |
Why?
|
| Spin Labels | 1 | 2014 | 25 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 1994 | 98 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 223 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 43 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2014 | 200 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 775 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2016 | 301 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 221 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2006 | 178 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 295 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 361 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 277 | 0.030 |
Why?
|
| Morphogenesis | 1 | 1994 | 198 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 393 | 0.020 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 1993 | 3 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 1992 | 122 | 0.020 |
Why?
|
| Meiosis | 1 | 1992 | 112 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 665 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 769 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 26 | 0.020 |
Why?
|
| Vinblastine | 1 | 2011 | 55 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 20 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1516 | 0.020 |
Why?
|
| Models, Genetic | 1 | 1994 | 751 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 59 | 0.020 |
Why?
|
| Camptothecin | 1 | 2011 | 78 | 0.020 |
Why?
|
| RNA Splicing | 1 | 1993 | 234 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 420 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 56 | 0.020 |
Why?
|
| RNA, Fungal | 1 | 1991 | 14 | 0.020 |
Why?
|
| Catalase | 1 | 1991 | 64 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 236 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 56 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1590 | 0.020 |
Why?
|
| Interferons | 1 | 2011 | 136 | 0.020 |
Why?
|
| Otitis Media with Effusion | 1 | 2011 | 30 | 0.020 |
Why?
|
| Copper | 1 | 1991 | 74 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 879 | 0.020 |
Why?
|
| Oocytes | 1 | 1992 | 283 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 86 | 0.020 |
Why?
|
| Sulfur Oxides | 1 | 1990 | 2 | 0.020 |
Why?
|
| Aerobiosis | 1 | 1990 | 13 | 0.020 |
Why?
|
| Anaerobiosis | 1 | 1990 | 14 | 0.020 |
Why?
|
| Sulfites | 1 | 1990 | 27 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 142 | 0.020 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 1 | 1990 | 30 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 286 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2297 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 221 | 0.020 |
Why?
|
| Cytosol | 1 | 1990 | 140 | 0.020 |
Why?
|
| Arsenates | 1 | 1989 | 20 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1989 | 18 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 441 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1989 | 144 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1991 | 1018 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 1069 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3344 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2005 | 3452 | 0.020 |
Why?
|
| Proteins | 1 | 1993 | 1025 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1831 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 999 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 576 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2464 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 1397 | 0.010 |
Why?
|
| Electrons | 1 | 2005 | 25 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2006 | 197 | 0.010 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2005 | 3 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2005 | 54 | 0.010 |
Why?
|
| Lectins | 1 | 2005 | 50 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 68 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 238 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2005 | 281 | 0.010 |
Why?
|
| Adipokines | 1 | 2005 | 121 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2005 | 228 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2004 | 76 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 2003 | 5 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 723 | 0.010 |
Why?
|
| Genotype | 1 | 1989 | 2655 | 0.010 |
Why?
|
| Respiration | 1 | 2003 | 120 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 121 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 143 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 773 | 0.010 |
Why?
|
| Movement | 1 | 2003 | 149 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 577 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 1313 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 553 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1610 | 0.010 |
Why?
|
| Enzyme Activation | 2 | 1993 | 588 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 1386 | 0.010 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 1995 | 32 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1995 | 155 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1995 | 135 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 1995 | 53 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 1995 | 56 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1995 | 148 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 609 | 0.010 |
Why?
|
| Mammals | 1 | 1995 | 258 | 0.010 |
Why?
|
| Guanine Nucleotides | 1 | 1993 | 13 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1993 | 20 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1992 | 41 | 0.010 |
Why?
|
| Microinjections | 1 | 1992 | 41 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1992 | 30 | 0.010 |
Why?
|
| GTPase-Activating Proteins | 1 | 1993 | 86 | 0.010 |
Why?
|
| Cyclins | 1 | 1992 | 94 | 0.010 |
Why?
|
| Tyrosine | 1 | 1992 | 148 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1995 | 588 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1992 | 106 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3113 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1992 | 692 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 1487 | 0.000 |
Why?
|
| Genetic Vectors | 1 | 1993 | 901 | 0.000 |
Why?
|